Skip to main content

Table 2 Recruiting and not yet recruiting trials for FAP-specific PET for non-malignant indications on clinicaltrials.gov

From: Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review

Title Estimated enrollment Estimated Study completion Date Indication Tracer Location Key Interventions
Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT 100 patients 10/2021 Arthritis Not specified Peking Union Medical College Hospital Patients who underwent FDG PET for suspected or confirmed untreated arthritis will receive and additional FAP-specific PET within two weeks
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT 100 patients 10/2021 Inflammatory bowel disease Not specified Peking Union Medical College Hospital Patients who underwent FDG PET for suspected or confirmed untreated inflammatory bowel disease will receive and additional FAP-specific PET within two weeks
Characterizing IgG4-RD With 68Ga-FAPI PET/CT 100 patients 10/2021 IgG4-related disease Not specified Peking Union Medical College Hospital Patients who underwent FDG PET for suspected or confirmed untreated IgG4-related disease will receive and additional FAP-specific PET within two weeks
68Ga-FAPI PET/CT in Liver Fibrosis Patients (GFAPILF) 50 patients 12/2023 Liver fibrosis 68Ga -FAPI-04 First Affiliated Hospital of Fujian Medical University Patients with suspected newly diagnosed or previously treated liver fibrosis will receive FAP-specific PET, transient elastography and blood testing
18F-FDG and 68Ga -FAPI PET/CT in Crohn's Disease 30 patients 09/2021 Crohn’s disease Not specified Peking Union Medical College Hospital Patients with Crohn’s disease with proofs of intestine stricture by other modalities (MRI/CT/ultrasound/endoscopy) will undergo FDG and FAP-specific PET within two days
In patients with resection of the stenotic intestine, the extent of inflammation and fibrosis will be analyzed